- Home
- NVAX vs TIC Comparison
NVAX vs TIC Comparison
Compare NVAX & TIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- TIC
- Stock Information
- Founded
- NVAX 1987
- TIC 1991
- Country
- NVAX United States
- TIC United States
- Employees
- NVAX N/A
- TIC N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- TIC
- Sector
- NVAX Health Care
- TIC
- Exchange
- NVAX Nasdaq
- TIC Nasdaq
- Market Cap
- NVAX 1.3B
- TIC 1.5B
- IPO Year
- NVAX 1995
- TIC N/A
- Fundamental
- Price
- NVAX $6.00
- TIC $9.70
- Analyst Decision
- NVAX Buy
- TIC Hold
- Analyst Count
- NVAX 6
- TIC 1
- Target Price
- NVAX $17.83
- TIC $13.00
- AVG Volume (30 Days)
- NVAX 6.0M
- TIC 256.8K
- Earning Date
- NVAX 05-09-2025
- TIC 05-27-2025
- Dividend Yield
- NVAX N/A
- TIC N/A
- EPS Growth
- NVAX N/A
- TIC N/A
- EPS
- NVAX N/A
- TIC N/A
- Revenue
- NVAX $682,162,000.00
- TIC $1,097,393,000.00
- Revenue This Year
- NVAX $1.07
- TIC N/A
- Revenue Next Year
- NVAX N/A
- TIC N/A
- P/E Ratio
- NVAX N/A
- TIC N/A
- Revenue Growth
- NVAX N/A
- TIC 4.51
- 52 Week Low
- NVAX $3.81
- TIC $2.39
- 52 Week High
- NVAX $23.86
- TIC $2.60
- Technical
- Relative Strength Index (RSI)
- NVAX 41.41
- TIC N/A
- Support Level
- NVAX $5.01
- TIC N/A
- Resistance Level
- NVAX $6.58
- TIC N/A
- Average True Range (ATR)
- NVAX 0.65
- TIC 0.00
- MACD
- NVAX 0.02
- TIC 0.00
- Stochastic Oscillator
- NVAX 50.25
- TIC 0.00
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.